66 related articles for article (PubMed ID: 27578099)
1. The molecular basis for the prolonged blood circulation of lipidated incretin peptides: Peptide oligomerization or binding to serum albumin?
Wang Y; Lomakin A; Kanai S; Alex R; Belli S; Donzelli M; Benedek GB
J Control Release; 2016 Nov; 241():25-33. PubMed ID: 27578099
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats.
Reddiar SB; Abdallah M; Styles IK; Müllertz OO; Trevaskis NL
Eur J Pharm Biopharm; 2024 Jul; 200():114339. PubMed ID: 38789061
[TBL] [Abstract][Full Text] [Related]
3. Genetically encoded discovery of perfluoroaryl macrocycles that bind to albumin and exhibit extended circulation in vivo.
Wong JYK; Ekanayake AI; Kharchenko S; Kirberger SE; Qiu R; Kelich P; Sarkar S; Li J; Fernandez KX; Alvizo-Paez ER; Miao J; Kalhor-Monfared S; John JD; Kang H; Choi H; Nuss JM; Vederas JC; Lin YS; Macauley MS; Vukovic L; Pomerantz WCK; Derda R
Nat Commun; 2023 Sep; 14(1):5654. PubMed ID: 37704629
[TBL] [Abstract][Full Text] [Related]
4. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics.
Zorzi A; Linciano S; Angelini A
Medchemcomm; 2019 Jul; 10(7):1068-1081. PubMed ID: 31391879
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
Nauck MA; Meier JJ
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):963-964. PubMed ID: 27651332
[No Abstract] [Full Text] [Related]
6. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
7. The physiological role of the brain GLP-1 system in stress.
Holt MK; Trapp S
Cogent Biol; 2016 Dec; 2(1):1229086. PubMed ID: 27722184
[TBL] [Abstract][Full Text] [Related]
8. Albiglutide: a unique GLP-1 receptor agonist.
Rendell MS
Expert Opin Biol Ther; 2016 Dec; 16(12):1557-1569. PubMed ID: 27677385
[TBL] [Abstract][Full Text] [Related]
9. iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy.
Lynch L; Hogan AE; Duquette D; Lester C; Banks A; LeClair K; Cohen DE; Ghosh A; Lu B; Corrigan M; Stevanovic D; Maratos-Flier E; Drucker DJ; O'Shea D; Brenner M
Cell Metab; 2016 Sep; 24(3):510-519. PubMed ID: 27593966
[TBL] [Abstract][Full Text] [Related]
10. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
Burcelin R; Gourdy P
Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 as a target for therapeutic intervention.
Rajeev SP; Wilding J
Curr Opin Pharmacol; 2016 Dec; 31():44-49. PubMed ID: 27591964
[TBL] [Abstract][Full Text] [Related]
12. The acute anorexic effect of liraglutide, a GLP-1 receptor agonist, does not require functional leptin receptor, serotonin, and hypothalamic POMC and CART activities in mice.
Nonogaki K; Kaji T
Diabetes Res Clin Pract; 2016 Oct; 120():186-9. PubMed ID: 27585115
[TBL] [Abstract][Full Text] [Related]
13. Human brain responses to gastrointestinal nutrients and gut hormones.
McLaughlin JT; McKie S
Curr Opin Pharmacol; 2016 Dec; 31():8-12. PubMed ID: 27580096
[TBL] [Abstract][Full Text] [Related]
14. Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice.
Sørensen G; Caine SB; Thomsen M
Alcohol Clin Exp Res; 2016 Oct; 40(10):2247-2252. PubMed ID: 27579999
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
16. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study.
Gastaldelli A; Gaggini M; Daniele G; Ciociaro D; Cersosimo E; Tripathy D; Triplitt C; Fox P; Musi N; DeFronzo R; Iozzo P
Hepatology; 2016 Dec; 64(6):2028-2037. PubMed ID: 27639082
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen deficiency is associated with improved glucose tolerance, and lower DPP-4 activity.
Kanno Y; Sakai A; Miyashita M; Tsuchida K; Matsuo O
Diabetes Res Clin Pract; 2016 Oct; 120():190-3. PubMed ID: 27592166
[TBL] [Abstract][Full Text] [Related]
18. Jejunal Infusion of Glucose Decreases Energy Intake to a Greater Extent than Fructose in Adult Male Rats.
Moghadam AA; Moran TH; Dailey MJ
J Nutr; 2016 Oct; 146(10):2124-2128. PubMed ID: 27581579
[TBL] [Abstract][Full Text] [Related]
19. Current and potential therapeutic targets of glucagon-like peptide-2.
Austin K; Markovic MA; Brubaker PL
Curr Opin Pharmacol; 2016 Dec; 31():13-18. PubMed ID: 27580097
[TBL] [Abstract][Full Text] [Related]
20. A Spectroscopic and Molecular Dynamics Study on the Aggregation Properties of a Lipopeptide Analogue of Liraglutide, a Therapeutic Peptide against Diabetes Type 2.
Giannetti M; Palleschi A; Ricciardi B; Venanzi M
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
